Key result
Allopurinol improves LVEF by ~19% in rats with chronic heart failure.
Why the study?
Does allopurinol improve myocardial energy metabolism and cardiac function in a rat model of chronic heart failure after myocardial infarction?
Does allopurinol improve myocardial energy metabolism and cardiac function in a rat model of chronic heart failure after myocardial infarction?
Absolute Event Rate: 87.1% vs 68.18%
p-value: p=<0.05
Allopurinol improves myocardial energy metabolism and cardiac function in a rat model of post-MI chronic heart failure, likely by regulating PGC-1α.
Provides preclinical support for allopurinol in post-MI heart failure; leaves open clinical translation pending human trials.
To determine the effect of the xanthine oxidase (XO) inhibitor allopurinol on myocardial energy metabolism in a chronic heart failure rat model after myocardial infarct.An AMI model was established in 6-week-old rats via the ligation of the anterior descending coronary artery. Thirty-five rats were randomly divided into the following 3 groups: an ALLO group, an AMI group, and a Sham group. Heart failure was successfully diagnosed via echocardiography and blood tests. Xanthine oxidase (XO), malondialdehyde (MDA), PGC-1α, CPT-1, and GLUT4 were monitored in the myocardium.The TEM results demonstrated that myofilament lysis and mitochondrial swelling were alleviated in the ALLO group compared with the AMI group (without ALLO). The results also demonstrated that cardiac function was significantly improved in the ALLO group compared with the AMI group. Compared with the AMI group, the ALLO group exhibited increased respiratory-chain enzyme activity, as well as increased PGC-1α and CPT-1 mRNA and protein expression, decreased MDA content, and decreased XO and GLUT4 mRNA and protein expression.ALLO improves myocardial energy metabolism in rats with chronic heart failure, which may result from the regulation of PGC-1α in the setting of glycolipid metabolism, enhancing the production of ATP.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2016) studied Chronic heart failure after myocardial infarction (n=35). Allopurinol vs. Normal saline (AMI control group) was evaluated on Left ventricular ejection fraction (LVEF) at 12 weeks (p=<0.05). Allopurinol improved cardiac function in rats with chronic heart failure, increasing left ventricular ejection fraction to 87.10% compared to 68.18% in the untreated myocardial infarction group.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: